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Abstract The aim of this study was to evaluate the
clinical effectiveness of covered Niti-S stent placement
under multidetector CT and fluoroscopy guidance for the
palliation of dysphagia in patients with cervical esophageal
cancer. Under radiological imaging guidance using axial
and sagittal CT scans, and fluoroscopy, Niti-S esophageal
stents were placed in ten consecutive patients with com-
plete obstruction caused by cervical esophageal cancer
(9 men and 1 woman; age range = 54–79 years; mean age
= 68.1 years) between February 2010 and December 2011.
The procedure time and technical success rate were eval-
uated. Swallowing improvement was assessed by the fol-
lowing items: ability to eat and/or swallow (graded as
follows: 3 = ability to eat normal diet, 2 = ability to eat
semisolids, 1 = ability to swallow liquids, 0 = complete
obstruction). Procedural and post-procedural complications
were also evaluated. Survival (mean ± SD) was examined.
The mean (±SD) procedure time was 40 ± 19 min (range
= 21–69 min). Stent placement was technically successful
in all patients; inadequate stent deployment did not occur
in any case. Ability to eat and/or swallow was improved
and scored 2.4 (score 3 in 5 cases, score 2 in 4 cases, score
1 in 1 case, and score 0 in no case) after stent place-
ment. No major or post-procedural complications were
encountered. The mean survival time was 131 ± 77 days
(range = 31–259 days). Niti-S stents appeared to be a safe
and effective device for the palliation of dysphagia caused
by advanced cervical esophageal cancer. Multidetector CT
and fluoroscopy image guidance helped the operators
accurately place the stents in the cervical esophagus.
Keywords Cervical esophageal cancer  Covered Niti-S
stent  Dysphagia  Palliative care  Radiological image
guidance  Deglutition  Deglutition disorders
Introduction
Malignant esophageal obstruction is caused by a primary
esophageal neoplasm in most patients [1]. Unfortunately,
despite recent advances in the curative treatment of
esophageal cancer, including combination chemotherapy
and radiotherapy, many patients present with the disease at
an incurable stage, requiring palliative treatment to relieve
dysphagia, which is often their main symptom [2, 3].
Self-expandable metal stents (SEMSs) were developed
with the advantage of having a smaller, more flexible
delivery system and increased ease of deployment [4].
Currently, covered stents are the most commonly used
SEMSs in patients with esophageal cancer because they
restrict tumor ingrowth through the metal mesh [5]. Covered
SEMSs also have been used successfully in the management
of patients with anastomotic leaks or fistulas [6]. Despite the
large number of different covered SEMSs available on the
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market, nitinol stents are widely used [7]. One of the most
commonly used nitinol-covered SEMSs worldwide is the
partially covered Ultraflex stent (Boston Scientific Japan,
Tokyo, Japan), because it is very flexible and exerts less
radial force; it is thus recommended to decrease the risk of
pain associated with the use of the stiffer devices [8–10].
It is essential to place the stent in the correct position for
it to be effective. It is very important to place the covered
SEMS correctly in a patient with cervical esophageal can-
cer, because if placed improperly, the patient may experi-
ence a troublesome foreign body sensation in the cervical
region or serious swallowing disturbance when the proxi-
mal end of the covered SEMS extends into the upper
esophageal orifice or hypopharynx [11, 12]. Some studies
reported that the placement of a conventional stent has been
relatively contraindicated in this region [12, 13]. The newly
designed covered Niti-S stent is fully covered to resist tissue
ingrowth, and it has an outer nitinol wire that reduces the
risk of stent migration. This covered SEMS does not
become shortened at the proximal end when it is deployed
so it is relatively easy to adjust its position [14, 15].
In the current study, Niti-S esophageal covered stents
were placed under multidetector CT and fluoroscopic
guidance to achieve precise placement, and the safety and
clinical effectiveness of the covered Niti-S stent for the




The institutional review board approved this study. Written
informed consent was obtained from the patients for all
procedures. Ten consecutive patients with complete dys-
phagia caused by advanced cervical esophageal cancer
(9 men and 1 woman; age range = 54–79 years; mean
age = 68.1 years) were enrolled in this prospective study
between February 2010 and December 2011. Squamous cell
carcinoma was confirmed pathologically in all patients. The
inclusion criteria were an inoperable, advanced malignant
obstruction of the cervical esophagus or recurrent dysphagia
after prior chemoradiation with curative or palliative intent
for esophageal cancer. A tumor was considered inoperable if
the patient had distant metastases or local tumor infiltration
in neighboring organs and/or poor general condition because
of concomitant disease. In two of ten patients, a tracheoe-
sophageal fistula was also present with a cervical esophageal
stricture. The upper end of the stricture was located at least
2.0 cm below the upper esophageal orifice on the endoscopic
findings in all cases. Exclusion criteria were tumor growth
within the upper esophageal orifice or lower hypopharynx,
previous stent placement, abnormal coagulation status (an
international normalized ratio value[1.5 and a platelet count
\70,000 mm3), poor general performance status, and unfit
to undergo conscious sedation. The primary end points of the
study were procedure duration time, technical success rate,
complications, and improvement of dysphagia. Secondary
outcomes included recurrent dysphagia, which was defined
as occurrence of tissue ingrowth or overgrowth, stent
migration, and mean survival time.
Stent Characteristics
The Niti-S stent (Taewoong Medical, Seoul, Korea) is a
compressed form inside an introducer sheath and is charac-
terized by a nitinol monofilament, fine mesh that is fully or
partly covered with polyurethane with a proximal flare of
26 mm, a body diameter of 18 mm, and a length of 80, 100,
or 120 mm. The proximal end of the stent is flared slightly
and has a tulip-like shape with an increase in diameter in
order to prevent migration. Moreover, this stent has a double-
layer configuration, with an outer uncovered nitinol wire
tube to allow the stent to fix itself in the esophageal wall
(Fig. 1). It becomes shortened by approximately 35 % from
the distal side when it is deployed, whereas the proximal end
does not become shortened. The delivery system has a 16-F
diameter, which is similar to that of the Ultraflex stent.
Stent Placement
All procedures for stent placement were performed by two
abdominal interventional radiologists (TF, MT) with 23 and
Fig. 1 Niti-S-covered esopha-
geal stent
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11 years of experience, respectively. An esophagram using
Iopamidol 300 (Iopamiron 300, Bayer Japan, Tokyo, Japan)
and conventional contrast-enhanced CT were obtained to
delineate the site and length of the cervical stricture and the
location of the tumor 3 or 4 days before stent placement
(Fig. 2). Barium was not used in patients with a tracheoe-
sophageal fistula because it could cause mediastinitis [16].
The location of the tracheoesophageal fistula was also
evaluated, i.e., its size and relationship with the esophageal
entrance, and the distance of the most proximal end of the
lesion from the incisors was carefully assessed. Esophageal
stents were inserted in the Interventional Radiology (IVR)-
CT (Somatom Sensation Open, Siemens, Erlangen, Ger-
many) suite under radiologic guidance and conscious
sedation without endoscopic assistance. This IVR-CT sys-
tem consisted of both a multidetector row CT scanner and
digital subtraction angiography (DSA), so that both a CT
scan and fluorography can be obtained in a single exami-
nation session. Pentazocine hydrochloride (Pentagin, Daii-
chi-Sankyo Healthcare Co., Ltd., Tokyo, Japan) as
premedication was injected intramuscularly to provide
conscious sedation, and lidocaine hydrochloride (Xylo-
caine, AstraZeneca K.K., Osaka, Japan) 10 % oral spray
was sprayed onto the posterior wall of the oropharynx to
reduce the gag reflex with the patient on the table in the
supine position. Oxygen (2 L/min) was administered via
nasal cannula, and the patient’s vital signs were monitored
continuously with pulse oximetry and electrocardiography.
The cervical CT examinations were performed with a 20-
detector row CT scanner. After acquisition of the topogram,
unenhanced axial images were obtained during a breath-
hold. The multidetector CT parameters were as follows:
detector configuration, 1.2 mm 9 20; table feed, 15 mm/
rotation; gantry rotation time, 0.7 s. Images were acquired
with a 2.0 mm slice thickness and reconstructed into
2.0 mm sections for interpretation. Axial and sagittal
multiplanar reconstructions (MPR) were automatically
generated to help the operators confirm the exact position of
the orifice of the upper esophageal sphincter (= esophageal
orifice) and the tumor location (Figs. 3 and 4). Next,
Fig. 2 Contrast-enhanced axial CT image a week before the stent
placement shows the esophageal cancer (arrow) in the cervical region
in a 64 year-old man
Fig. 3 Sagittal CT image obtained with an IVR-CT system imme-
diately before the stent placement demonstrates that cervical esoph-
ageal cancer (arrows) does not directly invade the hypopharynx
Fig. 4 Upper esophageal orifice (arrows) is clearly revealed on
unenhanced axial CT image
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radiopaque markers were placed on the body surface to
mark the appropriate position where it was planned to place
the proximal end of the stent below the upper esophageal
orifice by adhesive tape before the procedure. A 150 cm
long, 0.035 in. hydrophilic guide wire with a 45 angled,
3.0 cm soft tip (Radifocus guide wire, TERUMO Medical
Products, Tokyo, Japan) was carefully inserted into the
stomach through the stricture via the oral route under
fluoroscopic guidance. Then, the 4-Fr cobra-shaped angio-
graphic catheter was passed into the stomach over the guide
wire. After removing the Radifocus guide wire, a 260 cm-
long Amplatz stiff guide wire (COOK Japan, Tokyo, Japan)
was looped in the stomach or advanced into the proximal
duodenum, and the angiographic catheter was exchanged
for a 25 cm-long, 6-Fr angiographic sheath (Medikit,
Tokyo, Japan). The sheath was inserted into the distal side
of the stricture over the long, stiff guide wire. After
removing the sheath introducer, leaving the long stiff wire,
the location of the tumor was defined by contrast material
diluted with normal saline which was injected through the
side arm of the sheath above and below the esophageal
stricture. A Niti-S covered stent of appropriate size and
length was chosen and advanced across the stricture on its
delivery system. To prevent migration, it was deployed in
such a way that slightly more of the stent was above than
below the stricture. The length of the stent was chosen so at
least 2 cm of normal esophagus was covered by the stent
above and below the stricture. However, the proximal end
of the stent was never placed beyond the esophageal orifice
under the guidance of the body mark when the stricture was
located directly below the esophageal orifice (Fig. 5). Long
strictures may require more than one stent with a one-third
overlap between stents. After stent deployment, a 6-Fr long
sheath with introducer was again inserted over the wire, and
contrast material was injected to confirm the correct stent
position and rule out any complications such as perforation.
An esophagram and gastrointestinal endoscopy were
obtained a few days after to show that the stent had ade-
quately expanded in a satisfactory position and that the
tracheoesophageal fistula was completely occluded (Figs. 6
and 7). Preballoon dilatation of the stricture was not per-
formed in any case because the stent delivery system could
pass the esophageal stricture over the guide wire in all
cases. Immediate post-balloon dilatation after stent
deployment to avoid the stent migration was also not done
in any case.
Statistical Analysis
The procedure duration time from arrival at the IVR-CT unit
to completion of the entire procedure was recorded for all
patients. The technical success rate was evaluated after stent
placement. Moreover, patients received weekly follow-up
physical examinations or telephone calls from 28 days after
treatment until death. Assessment of improvement of dys-
phagia included the following items: ability to eat and/or
swallow (graded as follows: 3 = ability to eat a normal diet,
2 = ability to eat semisolids, 1 = ability to swallow liquids,
0 = complete obstruction). Procedural and post-procedural
Fig. 5 Covered Niti-S esophageal stent is deployed (arrow). The
radiopaque marker is placed on the body surface as the seventh
cervical vertebra (arrowhead)
Fig. 6 Endoscopic view of expanding Niti-S stent the day after
insertion
256 T. Fujita et al.: Covered Niti-S Stent for Dysphagia Palliation in Cervical Esophageal Cancer
123
complications were also evaluated. The procedural compli-
cations were perforation, aspiration, hemorrhage, stent
migration, and pain. Post-procedural complications included
perforation, hemorrhage, stent migration, pain or foreign
body sensation, and tumor ingrowth or overgrowth. All
available charts and records were reviewed in all cases.
Survival (mean ± SD) was calculated from the date of stent
placement to the date of death.
Results
The mean procedure time was 40 ± 19 (SD) min (range
= 21–69 min). Stent placement was technically successful
in all patients, and inadequate stent deployment did not
occur in any case. All stents were placed correctly at the
planned position, and no stent reached the upper esopha-
geal orifice. One stent was placed in eight cases and two
stents were placed in the remaining two cases. Ability to
eat and/or swallow improved and scored 2.4 (score 3 in 5
cases, score 2 in 4 cases, score 1 in 1 case, and score 0 in no
case) after stent placement. In two patients with tracheoe-
sophageal fistula and dysphagia, fistula sealing was also
achieved and fistula recurrence was not noted until death.
No major complications related to the procedure were
encountered and there was no procedure-related mortality.
No procedural complications, including esophageal
perforation and hemorrhage, occurred, and no patient
experienced severe pain at the site of stent placement
lasting more than 24 h that needed narcotic analgesics.
Three patients reported a moderate foreign body sen-
sation that was well tolerated and gradually disappeared by
the end of the first week after stent placement. The
remaining five patients tolerated the stent placement well in
the first few days with no further difficulties.
No post-procedural complications, including perforation,
hemorrhage, and stent migration, occurred, but recurrence of
dysphagia due to circumferential tumor overgrowth at the
proximal end of the stent was observed in two cases 22 and
46 days after stent placement, respectively. Reintervention
was not performed in these two cases because the patients
refused further therapy. Tumor ingrowth did not occur in
any case. The mean survival time was 131 ± 77 days
(range = 31–259 days).
Discussion
Obstruction of the esophagus leads to progressive dys-
phagia, malnutrition, and aspiration pneumonia. Dysphagia
is usually the most distressing symptom in patients with
inoperable malignancies of the esophagus, necessitating
immediate palliation [1, 17, 18].
Esophageal cancer located in the cervical region is
uncommon, accounting for 7–10 % of all esophageal
cancers [19]. Treatment for a tumor located in this region is
different from that for a tumor located in the intrathoracic
segment of the esophagus [19, 20].
The cervical esophagus endoscopically is between
approximately 15 and 20 cm from the incisor teeth and
radiologically projects above the sternoclavicular joint [21].
At that level in which the resting wall tension is high, which
is a high-pressure zone, any endoscopic procedure is more
problematic and troublesome, even in the presence of normal
anatomy, since long and flexible endoscopy of the hypo-
pharynx and upper esophageal sphincter is technically dif-
ficult due to the reduced efficacy of insufflation and
movements-related swallowing [12, 21]. Therefore, it is
relatively difficult to achieve exact placement of the stent in
patients with cervical cancer compared to other esophageal
regions with direct endoscopy guidance. Large series studies
of SEMS placement in cervical region are lacking [11, 12].
In addition, there have been few reports on the place-
ment of esophageal prostheses for cervical lesions because
of concerns about the high risk of proximal migration of
the stent into the hypopharynx and the intolerable foreign
body sensation, severe throat pain, and sudden upper
respiratory tract occlusion that may occur [22–24].
Currently, fluoroscopy has become the conventional
approach for guiding stent placement. Many studies have
Fig. 7 Contrast study shows satisfactory positioning and expansion
of the stent 2 days after deployment
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reported insertion of stents under radiologic guidance
without endoscopic assistance [13, 17, 25]. It is accepted
that the cervical esophagus is between the sixth cervical
vertebra at the pharyngoesophageal junction and the tho-
racic inlet at the first thoracic vertebra [21]. However, the
location of the cervical esophagus could vary among
individuals, and fluoroscopy does not always accurately
demonstrate the location of the upper esophageal orifice.
Even placement under fluoroscopy has limitations when
attempting exact positioning of the stent [21, 26].
Many studies have reported the usefulness of covered
SEMSs that were deployed under direct endoscopic visu-
alization and fluoroscopic guidance [14, 18, 23]. None-
theless, under endoscopic and fluoroscopic guidance,
Austin et al. [27] reported unsatisfactory stent positioning
for 7 of 30 patients with unresectable esophageal cancer.
Lazaraski et al. [8] also reported that the stent was not
accurately positioned when deployed in 7 of 89 patients
under endoscopic guidance. Misplacement of the stents has
occurred frequently and might diminish their therapeutic
efficacy.
It is not necessary to be as accurate with the placement
of a stent in the thoracic esophagus between the superior
margin of the sternum and the inferior tracheal bifurcation
because minor misplacement of the stent might not lead to
serious complications [11, 12]. However, it is very
important to precisely place a stent in the cervical esoph-
agus because stent misplacement may reduce its effec-
tiveness and cause unexpected complications. In patients
with cervical esophageal cancer, when the proximal end of
the SEMS reaches the upper esophageal orifice, it can
cause a swallowing disturbance or serious discomfort or
pain in the cervical region [11, 12, 22, 25]. Moreover, the
risk of cervical stenting relates to the possibility of proxi-
mal misplacement, which shares the danger of sudden
upper respiratory tract occlusion [11]. Mcdonald et al. [28]
reported that the upper limit of the stent is the fifth cervical
vertebra; however, some of their patients complained of a
foreign body sensation. Therefore, exact placement of the
stent is absolutely critical in patients with cervical esoph-
ageal cancer.
In the present study, CT guidance was used in addition
to fluoroscopy. To our knowledge, there have been no
studies reporting placement of an esophageal stent under
CT guidance. The IVR-CT system has the ability to obtain
fluoroscopy and thin-slice CT within one session. The
cervical anatomy and tumor location can be clearly dem-
onstrated by multidetector CT. We employed CT in the
present study because it provides detailed imaging of the
soft tissues and surrounding structures of the cervical
region within one diagnostic tour, allowing the safest
identification of the exact location for stent placement.
Furthermore, MPR images provide useful information on
the esophageal wall and the extension of tumor invasion.
The use of CT guidance has the potential of avoiding stent
misplacement.
The Niti-S stent used in the present series becomes
shortened at the distal end when it is deployed, so that
adjustment of the position of the proximal end of the stent
is relatively easy and misplacement can be avoided[14]. On
the other hand, the Ultraflex stent is difficult to place
exactly because both ends of the stent become shortened
when the stent is deployed. Also, because of its double
layer configuration with a membrane, migration of the Niti-
S stent is less likely [14, 15].
The present results indicate that the Niti-S stent can be
placed in the desired position under CT and fluoroscopic
guidance. Furthermore, the frequency of procedural and
post-procedural complications was almost equal to that of
other SEMSs [8, 9, 17].
There are three important limitations to this study. First,
this was a small study with a limited number of patients.
Therefore, randomized trials comparing the efficacies, risk
of complications, and recurrent dysphagia of covered stents
of various designs are needed, with particular attention
given to stent migration and tumoral and nontumoral tissue
overgrowth. Moreover, all procedures were performed by
only two experienced radiologists so the results might be
biased.
Second, in two patients, overgrowth of the tumor at the
proximal end of the stent occurred. In patients in whom the
tumor invaded directly below the esophageal orifice,
because the SEMS could not cover the proximal end of the
tumor, stent use in this region has limitations. Third, CT
with fluoroscopy might increase the cost of the procedure
compared to an endoscopic approach.
Conclusions
The present results demonstrate that the Niti-S stent is a
safe and effective device for the palliation of dysphagia
caused by inoperable or advanced cervical esophageal
cancer. The incidence of procedure-related complications
is comparable to that of other covered metal stents. The
outer wire of the Niti-S stent is likely to reduce stent
migration in patients with cervical esophageal cancer. The
distal shortening of the stent when it is deployed is also
helpful for avoiding proximal misplacement of the stent. In
addition, combined multidetector CT and fluoroscopic
image guidance provides the correct anatomical location to
the operator.
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